APA (7th ed.) Citation

PN, T., F, L., JB, L., RG, T., S, H., LS, S., . . . EM, R. (2018). The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort. Alzheimer's & dementia (New York, N. Y.), 4, 150. https://doi.org/10.1016/j.trci.2018.02.002

Chicago Style (17th ed.) Citation

PN, Tariot, et al. "The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A Study of Crenezumab Versus Placebo in Preclinical PSEN1 E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-dominant Alzheimer's Disease, Including a Placebo-treated Noncarrier Cohort." Alzheimer's & Dementia (New York, N. Y.) 4 (2018): 150. https://doi.org/10.1016/j.trci.2018.02.002.

MLA (9th ed.) Citation

PN, Tariot, et al. "The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A Study of Crenezumab Versus Placebo in Preclinical PSEN1 E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-dominant Alzheimer's Disease, Including a Placebo-treated Noncarrier Cohort." Alzheimer's & Dementia (New York, N. Y.), vol. 4, 2018, p. 150, https://doi.org/10.1016/j.trci.2018.02.002.